DOJ Intervenes in False Claims Act Case Against Insys Therapeutics

by Robinson+Cole Health Law Diagnosis
Contact

The Department of Justice (DOJ), recently intervened in a civil False Claims Act (FCA) case filed against Insys Therapeutics, Inc. (Insys) in the Central District of California that alleges FCA violations arising from the payment of kickbacks in violation of the Anti-Kickback Statute (AKS) as well as other fraudulent activities. Insys is an embattled Arizona-based pharmaceutical manufacturer of a highly-addictive sublingual opioid spray known as Subsys, and is currently the subject of a number of criminal and civil suits ongoing across the country (certain of which were consolidated into this case in connection with DOJ’s intervention). 

DOJ’s complaint in intervention describes how Insys allegedly paid kickbacks to physicians and nurse practitioners to induce providers to prescribe Subsys for their patients, including by allegedly (i) operating an extensive speaker’s bureau program that was in fact a sham designed to funnel payments to the speakers, (ii) hiring relatives and friends of providers to induce prescriptions of Subsys, and (iii) providing lavish meals and entertainment to providers to induce increased prescribing activities. DOJ also alleges that although Subsys was only approved by the FDA in narrow clinical circumstances for patients with “breakthrough cancer pain,” Insys “targeted its marketing efforts for Subsys to promote the drug  to treat patients who do not have cancer” and established an internal unit “dedicated to facilitating the process of obtaining prior authorization of Subsys prescriptions” from third party payors in order to increase sales by “l[ying] or making deliberately misleading statements… about material facts in order to obtain federal reimbursement for Subsys prescriptions that otherwise would not have been approved.”

The complaint further notes that a provision within the 2010 Patient Protection and Affordable Care Act revised the AKS to provide that any claims that include items or services resulting from a violation of the AKS constitute false or fraudulent claims actionable under the FCA. The complaint also expressly states that compliance with the AKS “is a material condition of payment by the Medicare program,” which could be read as an acknowledgment of the heightened importance of pleading evidence of materiality in an FCA case following the Supreme Court’s 2016 Escobar decision.

Interestingly, the DOJ complaint in intervention contains a rehashing of a series of recent criminal indictments and convictions of providers for allegedly receiving kickbacks from Insys, including cases against physicians in Alabama, Michigan, Rhode Island, and New York, as well as cases against non-physician practitioners with prescriptive authority (see here for our previous analysis of one of those cases). The complaint references 19 examples of providers receiving fees for sham speaking events from Insys, but not all of those providers appear to have been prosecuted. The complaint lists the amount of speaking fees allegedly paid to certain providers, as well as the amount paid by federal health care programs such as Medicare and TRICARE for Subsys prescriptions written by such providers during the same time period.

Finally, although DOJ (along with six states) intervened in part in the pending FCA actions, in its order unsealing certain of the cases the district court concurrently granted a request from the parties to stay the consolidated case pending “the resolution of” five criminal actions that relate to this FCA case (certain of which are described in the DOJ complaint). As a result, the case will be on hold until further order of the court while the criminal cases related to Insys move forward.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Robinson+Cole Health Law Diagnosis | Attorney Advertising

Written by:

Robinson+Cole Health Law Diagnosis
Contact
more
less

Robinson+Cole Health Law Diagnosis on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.